Close Menu

NEW YORK – AI precision medicine firm Tempus said Thursday that it has raised $200 million in a new Series G2 financing round, which will help expand the company's operations and establish activities in new disease areas including infectious diseases, depression, and cardiology.

Investors in the round included Baillie Gifford, Franklin Templeton, Google, Novo Holdings, and funds and accounts managed by T. Rowe Price. The new raise brings the firm's total financing to approximately $1.05 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.